Page last updated: 2024-11-10

vitamin k 1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

phylloquinone : A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5284607
CHEMBL ID1550
CHEBI ID18067
SCHEMBL ID351365
SCHEMBL ID3882
MeSH IDM0016826

Synonyms (163)

Synonym
MLS001074732
smr000112043
BIDD:GT0793
AKOS015841892
2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione
3-phytylmenadione
phyllochinonum
2-methyl-3-[(2e,7r,11r)-3,7,11,15-tetramethylhexadec-2-en-1-yl]naphthalene-1,4-dione
CHEBI:18067 ,
phytonadionum
fitomenadiona
2-methyl-3-[(2e)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone
phytomenadionum
alpha-phylloquinone
2-methyl-3-phytyl-1,4-naphthochinon
phytonadione, k1
hsdb 3162
2-methyl-3-phytyl-1,4-naphthochinon [german]
phytomenadionum [inn-latin]
1,4-naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, (r-(r*,r*-(e)))-
fitomenadione [dcit]
nsc 270681
antihemorrhagic vitamin
fitomenadiona [inn-spanish]
1,4-naphthalenedione, 2-methyl-3-((2e,7r,11r)-3,7,11,15-tetramethyl-2-hexadecenyl)-
vitamin k 1
einecs 201-564-2
1,4-naphthoquinone, 2-methyl-3-phytyl-
phyllochinon [german]
1,4-naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-
vitamin k1 (van)
2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalened- ione
mephyton
synthex p
mono-kay
combinal k1
phytylmenadione
monodion
kinadion
phytomenadione
phythyl-menadion
aquamephyton
k-ject
aqua mephyton
trans-phylloquinone
2',3'-trans-vitamin k1
kativ n
konakion
phyllochinon
nsc-270681
84-80-0
vitamin k1
phytonadione
phylloquinone
2-methyl-3-phytyl-1,4-naphthoquinone
vitamin k1, viscous liquid
phylloquinone (k1), analytical standard
DB01022
vitamin k1 (generic)
einecs 234-330-3
bdbm24782
vitamin k1, 11
2-methyl-3-[(2e,7r,11r)-3,7,11,15-tetramethylhexadec-2-en-1-yl]-1,4-dihydronaphthalene-1,4-dione
vitamin k1, bioxtra, >=99.0% (sum of isomers, hplc), mixtur of isomers
HMS2094G09
84C51B31-3CE2-476B-BE66-A84BDD46A513
phylloquinone e-form
CHEMBL1550
LMPR02030028
2-methyl-3-[(e,7r,11r)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione;vitamin k1
A840928
2-methyl-3-[(e,7r,11r)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione
phytonadione [usp:jan]
s5z3u87qhf ,
fitomenadione
unii-s5z3u87qhf
1,4-naphthalenedione, 2-methyl-3-((2e,7r,11r)-3,7,11,15-tetramethyl-2-hexadecen-1-yl)-
tox21_111655
dtxcid003472
cas-84-80-0
dtxsid8023472 ,
(r*,r*-(e))-(1)-2-methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone
phytonadione, (e)-(+/-)-
79083-00-4
mlf3d1712d ,
einecs 279-052-3
unii-mlf3d1712d
11104-38-4
nsc-760373
nsc760373
pharmakon1600-01505485
HMS2270J10
S4698
aqua-mephytin
A034SE7857 ,
veda-k1
mixture of the trans (e) and cis (z) isomers containing not less than 75% of trans-phytomenadione
veta-k1
CCG-213568
SCHEMBL351365
SCHEMBL3882
tox21_111655_1
NCGC00159423-03
2-methyl-3-((2e,7r,11r)-3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione
phytomenadione, (e)-
phytonadione [jan]
phylloquinone e-form [mi]
2-methyl-3-((7r,11r,e)-3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione
phylloquinone, (e)-
phytonadione, (e)-
Q-201934
1,4-naphthalenedione,2-methyl-3-[(2e,7r,11r)-3,7,11,15-tetramethyl-2-hexadecen-1-yl]-
1,4-naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, [r-[r*,r*-(e)]]-
W-108488
vitamink1
AB00698065_04
orakay
mfcd00214063
vitamin k1 (phylloquinone)
phytonadione, united states pharmacopeia (usp) reference standard
a-phylloquinone
2-methyl-3-phytyl-1,4-napthoquinone
SR-05000001941-1
sr-05000001941
phytonadione, pharmaceutical secondary standard; certified reference material
phytomenadione, european pharmacopoeia (ep) reference standard
SBI-0206926.P001
CS-6376
phylloquinone;2-methyl-3-phytyl-1,4-naphthoquinone
HY-N0684
vitamin k1; 2-methyl-3-phytyl-1,4-naphthoquinone
-2-enyl)naphthalene-1,4-dione
vitamin k1 ,(s)
2-methyl-3-((7r,11r,e)-3,7,11,15-tetramethylhexadec
2-methyl-3-((7r,11r,e)-3,7,11,15-tetramethylhexadec-2-enyl)naphthalene-1,4-dione
AS-13734
(e)-phytonadione
Q186093
1,4-naphthalenedione, 2-methyl-3-((2e,7r,11r)-3,7,11,15-tetramethyl-2-hexadecen-1-yl)-, rel-
rel-2-methyl-3-((7r,11r,e)-3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione
c31h46o2 (2-methyl-3-phytyl-1,4-naphthoquinone)
trans-phytomenadione 100 microg/ml in ethanol
AC-34846
konakion mm paed
neokay
bdbm50553259
konakion mm
kanavit
EN300-22411510
phylloquinone;phytomenadione
Z2568644345
phytonadionephytonadione
2-methyl-3-((2e,7r,11r)-3,7,11,15-tetramethylhexadec-2-en-1-yl)-1,4-naphthoquinone
2-methyl-3-((2e,7r,11r)-3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione
phytomenadione (ep impurity)
phytomenadione (mart.)
phytonadione (usp monograph)
vitaminum k1
2-methyl-3-((2e)-3,7,11,15-tetramethyl-2-hexadecenyl)naphthoquinone
5vet002 veta k-1
phytonadione (usp-rs)
2',3'-trans-phylloquinone
b02ba01

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Additionally, the elimination of Cremophor EL as well as of propylene glycol from the formulation avoids possible adverse effects associated with intravenous or intramuscular administration."( Pharmacokinetics and safety of a new solution of vitamin K1(20) in children with cholestasis.
Alagille, D; Amédée-Manesme, O; De Leenheer, AP; Lambert, WE, 1992
)
0.28
" Oral prophylaxis will probably be as safe as the intramuscular prophylaxis if given daily (25 microg) or weekly (1 mg)."( Oral versus intramuscular phytomenadione: safety and efficacy compared.
von Kries, R, 1999
)
0.3
" The main outcome measures were adverse reactions to intravenously administered phytonadione, prothrombin-international normalized ratio time values, the incidence of bleeding and thrombosis after the procedure, and the time between the procedure and return to anticoagulation after resumption of warfarin treatment."( Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy.
Heit, JA; Kuiper, JD; Li, H; McBane, RD; Shields, RC, 2001
)
0.31
"9%) of the 105 patients studied had suspected adverse reactions to intravenous phytonadione (dyspnea and chest tightness during infusion in both)."( Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy.
Heit, JA; Kuiper, JD; Li, H; McBane, RD; Shields, RC, 2001
)
0.31
"Intravenous phytonadione appears to be safe and is effective for semiurgent correction of long-term oral anticoagulation therapy before surgery."( Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy.
Heit, JA; Kuiper, JD; Li, H; McBane, RD; Shields, RC, 2001
)
0.31
" The secondary endpoints include adverse events of acneiform eruption and other adverse events."( A double-blind, placebo-controlled study of the safety and efficacy of vitamin K1 ointment for the treatment of patients with cetuximab-induced acneiform eruption.
Hamaguchi, T; Hashimoto, H; Honma, Y; Iwasa, S; Kato, K; Namikawa, K; Shimada, Y; Tsutsumida, A; Yamada, Y; Yamamoto, H; Yamazaki, N; Yanai, T, 2013
)
0.39
"Acne-like skin rash is a frequently occurring adverse event associated with drugs against the epidermal growth factor receptor."( EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
Al-Batran, SE; Ettrich, TJ; Feustel, HP; Heeger, S; Hofheinz, RD; Homann, N; Kripp, M; Lorenzen, S; Merx, K; Ocvirk, J; Schatz, M; Schulte, N; Schulz, H; Tetyusheva, M; Trojan, J; Vlassak, S, 2018
)
0.48

Pharmacokinetics

ExcerptReferenceRelevance
" In group I, the plasma half-life of the first component was between 18 and 52 min (median 23 min), and the half-life of the second was between 67 and 179 min (median 109 min)."( Pharmacokinetics of vitamin K1 in low-birth-weight neonates.
Bethenod, M; Bourgeay-Causse, M; Bourgeois, J; Frederich, A; Leclercq, M; Sann, L, 1985
)
0.27
"In 23 female and male healthy volunteers the pharmacokinetic behaviour of [3H]phenprocoumon and [3H]phytomenadion was investigated."( Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers.
Haustein, KO, 1984
)
0.27
" Pharmacokinetic analysis of plasma phylloquinone(vitamin K1) concentration vs time profiles revealed that in one-fifth of the subjects systemic availability of intramuscular phylloquinone (vitamin K1) was below 65%."( Pharmacokinetics and tolerance of intravenous and intramuscular phylloquinone (vitamin K1) mixed micelles formulation.
De Bruijn, EA; Grüter, J; Hanck, A; Maes, RA; Soedirman, JR, 1996
)
0.29
" For this reason, the study of the pharmacokinetic parameters of phenprocoumon (PPC), considering its influence on blood clotting factors, is of high interest."( Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon.
Haustein, KO, 1999
)
0.3
"During capecitabine treatment, the area under the plasma concentration time curve from 0 to infinity (AUC(0-infinity)) of S-warfarin increased by 57% (90% CI, 32% to 88%) with a 51% prolongation of the elimination half-life (t(1/2); 90% CI, 32% to 74%)."( Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer.
Abt, M; Camidge, R; Cassidy, J; Grange, S; Jodrell, D; Reigner, B; Weidekamm, E, 2005
)
0.33
"There is a significant pharmacokinetic interaction between capecitabine and S-warfarin, resulting in exaggerated anticoagulant activity."( Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer.
Abt, M; Camidge, R; Cassidy, J; Grange, S; Jodrell, D; Reigner, B; Weidekamm, E, 2005
)
0.33
"-1639 G > A to explore the relationship between genotype and pharmacokinetic parameters."( VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation.
Breuer, O; Coch, C; Hartmann, G; Kölsch, H; Lütjohann, D; Marinova, M; Mengel, M; Oldenburg, J; Stoffel-Wagner, B; Watzka, M; Westhofen, P, 2013
)
0.39
" Pharmacokinetic evaluation was performed using non-compartmental analysis."( VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation.
Breuer, O; Coch, C; Hartmann, G; Kölsch, H; Lütjohann, D; Marinova, M; Mengel, M; Oldenburg, J; Stoffel-Wagner, B; Watzka, M; Westhofen, P, 2013
)
0.39
"Pharmacokinetic analysis of serum phylloquinone concentration versus time profiles revealed significant differences in the main pharmacokinetic parameters between groups."( VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation.
Breuer, O; Coch, C; Hartmann, G; Kölsch, H; Lütjohann, D; Marinova, M; Mengel, M; Oldenburg, J; Stoffel-Wagner, B; Watzka, M; Westhofen, P, 2013
)
0.39
"-1639 G > A on the pharmacokinetic properties of phylloquinone could be demonstrated in humans."( VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation.
Breuer, O; Coch, C; Hartmann, G; Kölsch, H; Lütjohann, D; Marinova, M; Mengel, M; Oldenburg, J; Stoffel-Wagner, B; Watzka, M; Westhofen, P, 2013
)
0.39
" The pharmacokinetic analysis was performed using a non-compartmental approach."( A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study.
Darlington, JW; Gershkovich, P; Ibrahim, F; Sivak, O; Wasan, KM, 2014
)
0.4
" The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8."( A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study.
Darlington, JW; Gershkovich, P; Ibrahim, F; Sivak, O; Wasan, KM, 2014
)
0.4
" A higher dose of vitamin K1 should be used in future studies for accurate estimation of pharmacokinetic parameters."( A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study.
Darlington, JW; Gershkovich, P; Ibrahim, F; Sivak, O; Wasan, KM, 2014
)
0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
" Liver transplant patients receive a large number of medications and adverse drug reactions, and drug-drug interactions must be closely monitored."( Liver injury possibly related to drug interaction after liver transplant: a case report.
Jiang, WT; Liu, YH; Pan, C; Thian, Y; Zhu, LQ, 2014
)
0.4
"Close monitoring and prompt discontinuation of the drugs with high volume of distribution and metabolized through the liver are necessary to avoid drug-drug interaction in liver transplant patients."( Liver injury possibly related to drug interaction after liver transplant: a case report.
Jiang, WT; Liu, YH; Pan, C; Thian, Y; Zhu, LQ, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" A marked variability in the absorption rate of vitamin K-1 was found throughout the 18-hr period."( Diurnal rhythmicity of absorption of a lipid compound (vitamin K-1) in vivo in the rat.
Hollander, D; Kielb, M; Rim, E, 1978
)
0.26
" Increasing the bile salt concentration to 20 mM or the addition of long chain fatty acids, monoolein, or lecithin all resulted in significant (P less than 0-05) decrease in the absorption rate of the vitamin."( Factors affecting the absorption of vitamin K-1 in vitro.
Hollander, D; Rim, E, 1976
)
0.26
" Sensitive measures of vitamin K status were unaffected in a population where any significant decrease in phylloquinone bioavailability should have been reflected in those measures, indicating that 20 g olestra/d in the diet did not affect vitamin K status."( Vitamin K status of free-living subjects consuming olestra.
Ebert, ML; Jones, DY; Jones, MB; Koonsvitsky, BP; Lin, PY; Suttie, JW; Will, BH, 1991
)
0.28
" However, the bioavailability of vitamin K1 after administration of MM-K was poor (9."( The bioavailability of a mixed micellar preparation of vitamin K1, and its procoagulant effect in anticoagulated rabbits.
Park, BK; Pratt, SK; Scott, AK; White, PM; Winn, MJ, 1989
)
0.28
" Menadione, a good quinone reductase substrate, increased the elimination rate of orally administered ethanol thereby decreasing its bioavailability (as measured by the area under the curve (AUC) relating blood level to time) and its induced hepatic triglyceride accumulation."( Effects of vitamin K1 and menadione on ethanol metabolism and toxicity.
Cha, YN; Chung, JH; Rubin, RJ, 1993
)
0.29
" The administrations of phytonadione in a surfactant solution (preparation a) and in an oleic acid solution (preparations b) greatly increased the bioavailability of phytonadione."( Evaluation of bioavailability upon oral administration of phytonadione preparations in beagle dogs.
Kayano, M; Machida, Y; Nagai, T; Tokumura, T; Tsushima, Y, 1993
)
0.29
" It is concluded that the bioavailability of membrane-bound phylloquinone is extremely poor and may depend on other food components, notably fat."( Effect of food composition on vitamin K absorption in human volunteers.
Gijsbers, BL; Jie, KS; Vermeer, C, 1996
)
0.29
" There are currently no data on the relative bioavailability of dihydro-vitamin K1 but given its abundance in the American diet, this hydrogenated form of vitamin K warrants further investigation."( Dihydro-vitamin K1: primary food sources and estimated dietary intakes in the American diet.
Booth, SL; Pennington, JA; Sadowski, JA, 1996
)
0.29
"This randomized, controlled study evaluated the bioavailability of phylloquinone from an intravenous lipid emulsion."( Bioavailability of phylloquinone from an intravenous lipid emulsion.
Camilo, ME; Davidson, K; Jatoi, A; Mason, JB; O'Brien, M; Sadowski, JA; Sokoll, L, 1998
)
0.3
" Limited data suggest that the relative bioavailability of phylloquinone from vegetables is lower than that from a supplement."( Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults.
Booth, SL; Dallal, GE; Davidson, KW; Gundberg, CM; O'Brien-Morse, ME, 1999
)
0.3
"The objective of this study was to compare, in younger and older adults, the relative bioavailability of phylloquinone from a vegetable with that of a fortified oil."( Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults.
Booth, SL; Dallal, GE; Davidson, KW; Gundberg, CM; O'Brien-Morse, ME, 1999
)
0.3
" The relative bioavailability of phylloquinone was defined by the difference in plasma phylloquinone, percentage serum undercarboxylated osteocalcin (%ucOC), and urinary gamma-carboxyglutamic acid in response to 5 d of supplementation."( Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults.
Booth, SL; Dallal, GE; Davidson, KW; Gundberg, CM; O'Brien-Morse, ME, 1999
)
0.3
"There was no significant difference in the relative bioavailability of phylloquinone, as evidenced by the lack of a significant difference in plasma phylloquinone and %ucOC between the 2 groups after either the broccoli or oil diets for younger and older adults."( Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults.
Booth, SL; Dallal, GE; Davidson, KW; Gundberg, CM; O'Brien-Morse, ME, 1999
)
0.3
" Within the scope of this present study, it has not been possible to address issues such as inter-sample variability, losses during storage or the bioavailability from different foods and further work on these aspects is needed."( Compilation of a provisional UK database for the phylloquinone (vitamin K1) content of foods.
Bolton-Smith, C; Fenton, ST; Harrington, DJ; Price, RJ; Shearer, MJ, 2000
)
0.31
"The ability to study bioavailability of nutrients from foods is an important step in determining the health impact of those nutrients."( Isotopic labeling and LC-APCI-MS quantification for investigating absorption of carotenoids and phylloquinone from kale (Brassica oleracea).
Britz, SJ; Clevidence, BA; Kurilich, AC; Novotny, JA, 2003
)
0.32
" In rats, dihydro-K1 is well absorbed and detected in the tissues of the brain, pancreas, kidney, testis, abdominal aorta, liver and femur."( The biological activity and tissue distribution of 2',3'-dihydrophylloquinone in rats.
Hara, Y; Harada, H; Isobe, Y; Kamo, S; Konishi, S; Ozaki, R; Saitoh, S; Sato, T, 2003
)
0.32
"Vitamin K1 is poorly absorbed by the oral route in certain diseased conditions."( Quantitative effects of interacting variables on vitamin K1, phylloquinone, entrapment in liposomes.
Onaga, IC; Oyenuga, KO, 2001
)
0.31
" Therefore, the observed differences between K1 and MK-4 with respect to inhibition of arterial calcification may be explained by both differences in their tissue bioavailability and cofactor utilization in the reductase/carboxylase reaction."( Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats.
De Mey, JG; Schurgers, LJ; Soute, BA; Spronk, HM; Thijssen, HH; Vermeer, C,
)
0.13
" The 18O-labeled MK-4 was rapidly and remarkably well absorbed into the cells and metabolized to the epoxide form via a hydroquinone form as compared to the 18O-labeled PK."( Comparative uptake, metabolism, and utilization of menaquinone-4 and phylloquinone in human cultured cell lines.
Mizuguchi, Y; Murakami, A; Nakagawa, K; Okano, T; Suhara, Y, 2006
)
0.33
"Phylloquinone (vitamin K(1)) is a lipophilic compound present in plasma at low concentrations, which presents technical challenges for determining its bioavailability or metabolic fate using stable isotopes."( Measurement of deuterium-labeled phylloquinone in plasma by high-performance liquid chromatography/mass spectrometry.
Booth, SL; Dolnikowski, GG; Fu, X; Grusak, MA; Hdeib, M; Lichtenstein, AH; Peterson, JW, 2009
)
0.35
" Knowledge of the relative bioavailability of multiple vitamin K forms was also poor."( Vitamin K nutrition, metabolism, and requirements: current concepts and future research.
Booth, SL; Fu, X; Shearer, MJ, 2012
)
0.38
" The literature shows that the bioavailability from solutions might be higher than that from tablets, possibly resulting in different effects."( Vitamin K1 in oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects.
Gebuis, EP; Groeneveld, JJ; le Cessie, S; Lijfering, WM; Rosendaal, FR; van der Horst, FA; van der Meer, FJ; van Rein, N, 2014
)
0.4
"To compare the bioavailability and effect on the International Normalized Ratio (INR) of 5-mg VK1 tablets and solution in three randomized clinical trials."( Vitamin K1 in oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects.
Gebuis, EP; Groeneveld, JJ; le Cessie, S; Lijfering, WM; Rosendaal, FR; van der Horst, FA; van der Meer, FJ; van Rein, N, 2014
)
0.4
"The bioavailability was determined in a crossover trial with 25 healthy volunteers."( Vitamin K1 in oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects.
Gebuis, EP; Groeneveld, JJ; le Cessie, S; Lijfering, WM; Rosendaal, FR; van der Horst, FA; van der Meer, FJ; van Rein, N, 2014
)
0.4
"To develop a stable micellar formulation of vitamin K for oral delivery, because the commercial and clinically used formulation of vitamin K (Konakion® MM) destabilizes at gastric pH resulting in low bioavailability of this vitamin in neonates with cholestasis."( A Mixed Micelle Formulation for Oral Delivery of Vitamin K.
Hennink, WE; Jaspers, TC; Sun, F; van Hasselt, PM; van Nostrum, CF, 2016
)
0.43
"Owing to its limited aqueous solubility, Phytomenadione (vitamin K) undergoes a low bioavailability (50%) with a large inter-individual variability after oral administration."( Fabrication and evaluation of Phytomenadione as a nanostructure lipid carrier for enhancement of bioavailability.
Aljaeid, BM; Hosny, KM, 2018
)
0.48
" Menaquinone-7 has greater bioavailability than other forms of vitamin K, which has led to increasing sales and use of menaquinone-7 supplements."( US Pharmacopeial Convention safety evaluation of menaquinone-7, a form of vitamin K.
Marles, RJ; Oketch-Rabah, HA; Roe, AL, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" MK-7 has higher efficacy due to its higher bioavailability and longer half-life than other vitamin K homologs."( MK-7 and Its Effects on Bone Quality and Strength.
Inaba, N; Sato, T; Yamashita, T, 2020
)
0.56
" Among these, MK7 is the most efficient in terms of bioavailability and biological effect."( Carboxylative efficacy of trans and cis MK7 and comparison with other vitamin K isomers.
Cirilli, I; Dludla, PV; Kaesler, N; Marcheggiani, F; Orlando, P; Silvestri, S; Tiano, L, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" This dosing regimen creates an extrahepatic vitamin K deficiency while preserving the vitamin K-dependent processes of the liver."( The warfarin embryopathy: a rat model showing maxillonasal hypoplasia and other skeletal disturbances.
Howe, AM; Webster, WS, 1992
)
0.28
"A proper dosage of warfarin after artificial cardiac valve replacements has been determined as an indication of coagulation activity."( Variations in warfarin concentration in blood and coagulant factors after artificial valve replacement.
Ishibashi, M; Kariyazono, H; Nakamura, K; Shimokawa, S; Taira, A; Toyohira, H, 1992
)
0.28
" The blood was obtained from animals after single and multiple dosing of drugs."( Phytomenadione improves red cell deformability in laboratory animals.
Jakovljević, V; Sabo, A; Stanulović, M, 1992
)
0.28
" Serum brodifacoum concentrations were highest (1065-1215 ng/mL) during the 3 days after BDF dosing and were detectable (3."( Coagulopathic effects and therapy of brodifacoum toxicosis in dogs.
Green, RA; Murphy, MJ; Ray, AC; Woody, BJ,
)
0.13
" Two dose finding studies in patients with various degrees of renal insufficiency revealed that the dosage of flomoxef has to be reduced exactly according to the renal function."( Pharmacokinetics and hemostasis following administration of a new, injectable oxacephem (6315-S, flomoxef) in volunteers and in patients with renal insufficiency.
Andrassy, K; Gorges, K; Hirauchi, K; Koderisch, J; Sonntag, H, 1991
)
0.28
" This dosing regimen did not have any apparent deleterious effect on the dams and did not affect the fetuses when administered from day 1 to day 12 of pregnancy."( Exposure of the pregnant rat to warfarin and vitamin K1: an animal model of intraventricular hemorrhage in the fetus.
Howe, AM; Webster, WS, 1990
)
0.28
" Vitamin K3 was also cytotoxic in the same dosage range when tested in vitro against the 34 human tumor explants in the soft agar assay system."( Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation.
Akman, S; Block, JB; Chlebowski, RT; Dietrich, M, 1985
)
0.27
"The effect of liposomally-associated vitamin K1, administered orally, was investigated using rabbits with warfarin-induced hypoprothrombinaemia, and evaluated in comparison with other dosage forms of the vitamin, including a vitamin K1 emulsion, the physical mixture of the emulsion with empty liposomes, polyoxyethylene hydrogenated castor oil (HCO-60)-stabilized emulsion and the vitamin solubilized by HCO-60."( Coagulation recovery after warfarin-induced hypoprothrombinaemia by oral administration of liposomally-associated vitamin K1 to rabbits.
Ikeda, K; Nagata, M; Nonomura, M; Yotsuyanagi, T, 1984
)
0.27
"Patients (40 cases) were treated with daily dosage of warfarin of 2-7 mg after being undergone artificial valve replacements."( Anticoagulant effects of warfarin and kinetics of K vitamins in blood and feces.
Ishibashi, M; Kariyazono, H; Nakamura, K; Saigenji, H; Shimokawa, S; Taira, A; Toyohira, H, 1994
)
0.29
" After 48 h (day 2), warfarin dosage was changed according to the INR value."( Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation.
Banzato, A; Biasiolo, A; Garelli, E; Pengo, V; Zasso, A, 1993
)
0.29
" Following stabilization of daily warfarin dosage 1 mg doses of the extracted MK were orally administered."( The absorption and bioactivity of bacterially synthesized menaquinones.
Conly, JM; Stein, KE, 1993
)
0.29
" Riboflavin decreased SCEs induced by Trp-P-2 in all treatment schedules, although statistically confirmed minima were observed in the dose-response curves, except in post-treatment experiments."( Effects of beta-carotene, retinal, riboflavin, alpha-tocopherol and vitamins C and K1 on sister-chromatid exchanges induced by 3-amino-1-methyl-5H-pyrido[4,3-b]indole (Trp-P-2) and cyclophosphamide in human lymphocyte cultures.
Dunkelberg, H; Edenharder, R; Kerkhoff, G, 1998
)
0.3
" (2) The oral route is suitable for healthy term neonates, but dosing must be repeated if the infant is mainly breastfed."( Prevention of haemorrhagic disease of the newborn. Routine vitamin K1 administration is justified.
, 1998
)
0.3
" Correlation analysis of data showed that warfarin dosage was significantly and negatively correlated with patient age (r = -0."( The influence of (R)- and (S)-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation.
Butler, TJ; Edwards, C; Kamali, F; Wynne, HA, 2000
)
0.31
"The patients' medical records were evaluated; data were collected on patient demographics and on vitamin K1 dosage and route of administration, warfarin dosage, and international normalized ratio (INR) before and after vitamin K1 administration."( A retrospective evaluation of vitamin K1 therapy to reverse the anticoagulant effect of warfarin.
Adams, AG; Armitstead, JA; Davis, GA; Fan, J, 2003
)
0.32
" The results indicated that the lower dosage could not reverse the anticoagulation process, however the period of mortality was considerably increased from 3-9 days (in control) to 5-14 days (5 days supplementation regime)."( Effect of supplementary feeding of vitamin K1 on difethialone treated Indian gerbil, Tatera indica Hardwicke in laboratory.
Chaudhary, V; Poonia, FS; Tripathi, RS, 2004
)
0.32
" The results of two dose-response studies have indicated that the amount of vitamin K needed for optimal gamma-carboxylation of osteocalcin is significantly higher than what is provided through diet alone and that current dosage recommendations should be increased to optimize bone mineralization."( Vitamin K in the treatment and prevention of osteoporosis and arterial calcification.
Adams, J; Pepping, J, 2005
)
0.33
" A less severe bleeding or asymptomatic increase in the international normalized ratio can be treated effectively by skipping or decreasing of the warfarin dosage and/or oral administration of vitamin K1 (i."( [Hemorrhagic complications during warfarin treatment].
Blatný, J; Brejcha, M; Gumulec, J; Kessler, P; Klaricová, K; Klodová, D; Králová, S; Lasota, Z; Penka, M; Riedlová, P; Sumná, E; Wróbel, M, 2006
)
0.33
" Recent epidemiological studies provide data on the effectiveness of different administration routes and dosing schemes."( Vitamin K, an update for the paediatrician.
De Bruyne, R; Van Biervliet, S; Van De Velde, S; Van Winckel, M, 2009
)
0.35
" With high dosage of vitamin K1 and fresh frozen plasma therapy, surgery was avoided."( Superwarfarin poisoning as a cause of intestinal obstruction.
Cao, Y; Du, XD; Nie, H; Wei, W, 2010
)
0.36
"An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit."( Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.
Berube, C; Lee, R; Wen, A, 2011
)
0.37
"0 at a weekly warfarin dosage of 52."( Elevated international normalized ratio values associated with concomitant use of warfarin and ceftriaxone.
Burns, S; Clark, TR, 2011
)
0.37
"017), dosing errors (p=0."( Effect of 200μG/day of vitamin K1 on the variability of anticoagulation control in patients on warfarin: a randomized controlled trial.
Carrier, M; Forgie, M; Gonsalves, C; Majeed, H; Rodger, M; Rodriguez, RA; Scarvelis, D; Taljaard, M; Wells, PS, 2013
)
0.39
"Plasma concentration-time profiles of VK1 were investigated in rats after dosing VKLE or VKI at the range of 1-4 mg/kg."( Pharmacokinetics and pharmacodynamics of two vitamin K1 formulations in rats.
Cao, Y; Chen, L; Ma, L; Xiao, Q; Yang, J, 2015
)
0.42
" The dosage of warfarin was adjusted to keep the INR within 2-3 in all patients."( Periprocedural anticoagulation of patients undergoing pericardiocentesis for cardiac tamponade complicating catheter ablation of atrial fibrillation.
Bai, R; Chen, YW; Dong, JZ; Li, SN; Lin, T; Ma, CS; Sang, CH; Tang, RB; Yu, RH, 2015
)
0.42
"Warfarin is characterized by a large inter-individual variability in dosage requirement."( Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.
Akimoto, T; Hayashi, H; Hirai, K; Inoue, K; Itoh, K; Izumiya, K; Moriwaki, H; Suzuki, M; Tanaka, M; Tsuji, D; Yamada, Y; Yoshizawa, M, 2015
)
0.42
" In contrast, plasma VK1 and MK-4 concentrations were not significantly associated with warfarin dosage in patients."( Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.
Akimoto, T; Hayashi, H; Hirai, K; Inoue, K; Itoh, K; Izumiya, K; Moriwaki, H; Suzuki, M; Tanaka, M; Tsuji, D; Yamada, Y; Yoshizawa, M, 2015
)
0.42
" The CYP4F2 polymorphism is poorly associated with inter-individual variability of warfarin dosage requirement."( Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.
Akimoto, T; Hayashi, H; Hirai, K; Inoue, K; Itoh, K; Izumiya, K; Moriwaki, H; Suzuki, M; Tanaka, M; Tsuji, D; Yamada, Y; Yoshizawa, M, 2015
)
0.42
" The predicted warfarin-binding site was verified by shifted dose-response curves of specified mutated residues."( Warfarin and vitamin K compete for binding to Phe55 in human VKOR.
Biswas, A; Czogalla, KJ; Höning, K; Hornung, V; Liphardt, K; Oldenburg, J; Watzka, M, 2017
)
0.46
" The patients' sex, age, coagulation function, total time from poisoning to treatment with vitamin K1 (prehospital time), vitamin K1 sustained treatment time (VKSTT), anticoagulant rodenticide category, and specific poison dosage were collected."( Treatment of a long-acting anticoagulant rodenticide poisoning cohort with vitamin K1 during the maintenance period.
Lin, G; Long, J; Luo, Y; Peng, X; Qiu, Z; Sun, Y; Wang, Y, 2016
)
0.43
" This formula could be a promising carrier regarding its ease of preparation, dosage form versatility and enhanced bioavailability."( Fabrication and evaluation of Phytomenadione as a nanostructure lipid carrier for enhancement of bioavailability.
Aljaeid, BM; Hosny, KM, 2018
)
0.48
" On the basis of this conclusion, US Pharmacopeia monographs have been developed to establish quality standards for menaquinone-7 as a dietary ingredient and as a dietary supplement in various dosage forms."( US Pharmacopeial Convention safety evaluation of menaquinone-7, a form of vitamin K.
Marles, RJ; Oketch-Rabah, HA; Roe, AL, 2017
)
0.46
" Despite being at risk for VKDB, there are no studies comparing vitamin K versus non-treatment and few studies that address potential dosing strategies for effective treatment."( Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates.
Ardell, S; Offringa, M; Ovelman, C; Soll, R, 2018
)
0.48
" low-molecular-weight heparin (LMWH) was regarded as a preferable option, and nadroparin at the dosage of 4100IU daily was administered."( The optimal anticoagulant therapy for mechanical heart valves in a gallbladder cancer patient with hepatic metastases: A case report.
Chen, BY; Cui, JJ; Gu, ZC; Su, YJ; Xu, Q; Yan, YD; Zhang, ZL, 2018
)
0.48
"Two consecutive experiments, each lasting 4 weeks, were required to modify the dosing schedule of warfa-rin and VK1 and to adapt it to the Wistar rats used."( Experimental Model of Subclinical Vitamin K Deficiency.
Gancheva, S; Ghenev, P; Kitanova, M; Zhelyazkova-Savova, M, 2020
)
0.56
"The original dosing schedule induced VK deficiency, manifested by arterial calcifications and dramatic changes in carboxyl-ated and uncarboxylated osteocalcin."( Experimental Model of Subclinical Vitamin K Deficiency.
Gancheva, S; Ghenev, P; Kitanova, M; Zhelyazkova-Savova, M, 2020
)
0.56
" The challenge of VKAs therapy is their narrow therapeutic index and highly variable dosing requirements, which are partially the result of genetic variations of VKOR."( A novel vitamin K derived anticoagulant tolerant to genetic variations of vitamin K epoxide reductase.
Chen, X; Furukawa, N; Jin, DY; Liu, Y; Paul Savage, G; Stafford, DW; Suhara, Y; Tie, JK; Williams, CM, 2021
)
0.62
"816), were found to be inversely associated with the risk of pancreatic cancer in a nonlinear dose-response manner (all P values for nonlinearity < 0."( Dietary Vitamin K Intake and the Risk of Pancreatic Cancer: A Prospective Study of 101,695 American Adults.
Cheng, L; Gong, JP; Hu, JJ; Li, QJ; Peng, Y; Sun, WP; Wu, JJ; Yang, PF; Yu, DW; Zhong, GC, 2021
)
0.62
" During the maintenance treatment period, the VK1 dosage was positively correlated with blood LAAR concentration."( Retrospective analysis of clinical characteristics of and treatment strategies for patients with long-acting anticoagulant rodenticide poisoning.
Guodong, L; Jianguang, D; Jieyi, W; Xiaobo, P; Xiaoxia, L; Zewu, Q; Zhiguo, P; Zhongying, L, 2022
)
0.72
" However, further randomized clinical studies are needed to assess the safety and the adequate dosage to prevent these CKD complications."( Role of Vitamin K in Chronic Kidney Disease: A Focus on Bone and Cardiovascular Health.
Andreucci, M; Bellone, F; Bolignano, D; Carullo, N; Casarella, A; Cinquegrani, M; Coppolino, G; De Sarro, G; Mandraffino, G; Nicotera, R; Presta, P; Prunestì, M; Squadrito, G; Vocca, C, 2022
)
0.72
"This study sought to characterize differences in responders and nonresponders to high-dose vitamin K to guide dosing strategies."( Evaluation of Response to High-Dose Intravenous Vitamin K Administration.
Bass, SN; Chapman, AR; Lumpkin, M; Militello, M; Rudoni, MA; Wang, L; Yerke, JR, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
cofactorAn organic molecule or ion (usually a metal ion) that is required by an enzyme for its activity. It may be attached either loosely (coenzyme) or tightly (prosthetic group).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
phylloquinones
vitamin KAny member of a group of fat-soluble 2-methyl-1,4-napthoquinones that exhibit biological activity against vitamin K deficiency. Vitamin K is required for the synthesis of prothrombin and certain other blood coagulation factors.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (26)

PathwayProteinsCompounds
Enoxaparin Action Pathway213
Fondaparinux Action Pathway213
Heparin Action Pathway213
Ardeparin Action Pathway213
Argatroban Action Pathway203
Bivalirudin Action Pathway202
Lepirudin Action Pathway202
Ximelagatran Action Pathway203
Alteplase Action Pathway202
Anistreplase Action Pathway202
Streptokinase Action Pathway202
Tenecteplase Action Pathway202
Urokinase Action Pathway202
Reteplase Action Pathway202
Aminocaproic Acid Action Pathway203
Tranexamic Acid Action Pathway203
Aprotinin Action Pathway202
Warfarin Action Pathway203
Acenocoumarol Action Pathway203
Dicumarol Action Pathway203
Phenprocoumon Action Pathway203
Coagulation202
Phenindione Action Pathway203
Dicoumarol Action Pathway203
Vitamin K metabolism and activation of dependent proteins1212
vitamin K1218

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency27.48220.006038.004119,952.5996AID1159521; AID1159523
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency15.35870.01237.983543.2770AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.68320.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency33.49150.003041.611522,387.1992AID1159552
GVesicular stomatitis virusPotency38.90180.01238.964839.8107AID1645842
aryl hydrocarbon receptorHomo sapiens (human)Potency19.71720.000723.06741,258.9301AID743085; AID743122
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency29.84930.000323.4451159.6830AID743065
DNA polymerase eta isoform 1Homo sapiens (human)Potency50.11870.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624296
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency56.23416.309660.2008112.2020AID720707
Interferon betaHomo sapiens (human)Potency38.90180.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency29.84930.002319.595674.0614AID651631
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-synucleinHomo sapiens (human)IC50 (µMol)15.00000.19003.82049.8000AID1695743
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (258)

Processvia Protein(s)Taxonomy
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (74)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (54)

Processvia Protein(s)Taxonomy
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (93)

Assay IDTitleYearJournalArticle
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID336953Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1695743Inhibition of wild type human alpha-synuclein fibrillization expressed in Escherichia coli BL21(DE3)pLysS by thioflavin-T based fluorescence assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID608159Agonist activity at human FLAG-tagged SXR ligand binding domain expressed in human HepG2 cells co-transfected with pGVP2-Gal4 vector assessed as induction of CYP3A4 gene expression at 5 x 10'-6 M after 48 hrs by dual-luciferase reporter gene assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Synthesis of new vitamin K analogues as steroid and xenobiotic receptor (SXR) agonists: insights into the biological role of the side chain part of vitamin K.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID336958Cytotoxicity against human Raji cells assessed as cell viability at 500 molar ratio
AID336956Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID336959Cytotoxicity against human Raji cells assessed as cell viability at 100 molar ratio
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1774079Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1774078Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1774076Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID326467Inhibition of purified human recombinant IDO2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1774075Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID336954Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID603957Octanol-water partition coefficient, log P of the compound2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID336960Cytotoxicity against human Raji cells assessed as cell viability at 10 molar ratio
AID336955Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID336957Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,599)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990587 (36.71)18.7374
1990's246 (15.38)18.2507
2000's313 (19.57)29.6817
2010's320 (20.01)24.3611
2020's133 (8.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.14 (24.57)
Research Supply Index7.51 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index131.17 (26.88)
Search Engine Supply Index3.62 (0.95)

This Compound (44.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials131 (7.71%)5.53%
Reviews122 (7.18%)6.00%
Case Studies131 (7.71%)4.05%
Observational14 (0.82%)0.25%
Other1,301 (76.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (32)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Vitamin K Supplementation on Bone Health Indices in Adult Crohn's Disease [NCT01235325]Phase 470 participants (Actual)Interventional2008-07-31Completed
Effect of Vitamin K in Critically Ill Patients With Spontaneously Increased Pro-thrombin Time Measured With Routine Coagulation Tests and Advanced Coagulation- and Vitamin K-assays [NCT03782025]52 participants (Actual)Observational2019-02-13Completed
Comparison of Efficacy of Different Dosages Vitamin K2 [NCT01194778]82 participants (Actual)Interventional2009-10-31Completed
A Study to Evaluate the Effect of Multiple Doses of 500 mg of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan Dosed Orally and Midazolam Dosed IV, in Healthy Male Volunteers [NCT02256813]Phase 120 participants (Actual)Interventional2005-09-30Completed
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) [NCT04752813]Phase 250 participants (Anticipated)Interventional2023-09-28Recruiting
Dietary and Non-dietary Components of Vitamin K Metabolism [NCT00336232]59 participants (Actual)Interventional2006-05-31Completed
Multicenter Randomized Controlled Trial of Vitamin K1 in the Treatment of Spontaneous Intracerebral Hemorrhage [NCT03388970]Early Phase 1400 participants (Anticipated)Interventional2017-08-01Enrolling by invitation
The Additive Effect of Vitamin K Supplementation and Bisphosphonate on Fracture Risk in Post-menopausal Osteoporosis [NCT01232647]Phase 2/Phase 3105 participants (Actual)Interventional2015-04-30Active, not recruiting
Vitamin K Supplementation to Improve INR Stability in Patients on Hemodialysis Taking Warfarin for Atrial Fibrillation [NCT02324686]Phase 23 participants (Actual)Interventional2014-01-31Completed
A Single-center, Single-arm, Open-label, Fixed-sequence, Self-controlled Study of the Effects of HRS5091 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin and Rosuvastatin in Healthy Volunteers [NCT05273775]Phase 122 participants (Actual)Interventional2022-04-29Completed
A Phase III Pilot RCT (Randomized, Controlled Trial) to Assess the Effectiveness of Low Dose Vitamin K1 (200 Micrograms Per Day) on Improving Anticoagulation Control in Unstable Patients on Warfarin [NCT00794755]Phase 3100 participants (Anticipated)Interventional2008-11-30Completed
Real Life Experience in the Management of HCV Related Decompensated Cirrhosis With Direct Antiviral Agents [NCT03547895]80 participants (Actual)Interventional2015-06-01Completed
A Multicentre Study of Low Dose Oral Vitamin K for INR Control in Patients Receiving Warfarin [NCT00990158]Phase 3235 participants (Actual)Interventional2010-07-31Completed
Incorporation of Vitamin K Into Uremic Lipoproteins [NCT05360342]20 participants (Actual)Interventional2020-03-31Completed
Effects of Fhytomenadione on Coronary Artery Calcification of Hemodialysis Patients. Randomized Clinical Trial [NCT04247087]60 participants (Actual)Interventional2017-09-07Completed
[NCT00905229]0 participants (Actual)Interventional2009-05-31Withdrawn(stopped due to Enrollment problems)
Vitamin K and Bone Turnover in Postmenopausal Women [NCT00062595]Phase 3375 participants Interventional2000-09-30Completed
Better Evidence and Translation for Calciphylaxis [NCT05018221]Phase 3350 participants (Anticipated)Interventional2021-08-26Recruiting
A Single-center, Open-label, Single-arm, Fixed-sequence Study to Evaluate the Pharmacokinetic Effects of SHR0302 Tablets on Substrates of CYP3A4, CYP2C8, CYP2C9, CYP2C19 in Healthy Volunteers [NCT05392127]Phase 124 participants (Actual)Interventional2022-07-15Completed
Evaluation of the Clinical Use of Vitamin K Supplementation in Post-Menopausal Women With Osteopenia (ECKO Trial) [NCT00150969]Phase 3440 participants (Actual)Interventional2002-01-31Completed
Use of Phytonadione to Reduce INR Variability in Patients on Long-term Warfarin Therapy [NCT01474460]370 participants (Actual)Interventional2011-09-30Completed
A Multicentre, Multinational Study of Oral Vitamin K for the Treatment of Warfarin Associated Coagulopathy [NCT00143715]Phase 3690 participants (Actual)Interventional2004-09-30Completed
Inhibit Progression of Coronary Artery Calcification With Vitamin K in HemoDialysis Patients: The iPACK-HD Study [NCT01528800]Phase 285 participants (Actual)Interventional2012-11-30Completed
Study of the Effect of Food Vitamin K2 Intake in Association With a Fermented Dairy Product on Patients Treated With Vitamin K Antagonist (VKA) [NCT01533441]Phase 250 participants (Actual)Interventional2012-02-29Completed
Comparison of Effects of Nutritional Doses Vitamin K1 and K2 on Carboxylation [NCT01638182]81 participants (Actual)Interventional2011-03-31Completed
Vitamin K1 to Slow Progression of Vascular Calcification in Hemodialysis Patients [NCT01742273]Phase 363 participants (Actual)Interventional2013-10-31Terminated(stopped due to Termination stopped due to low recruitment rates)
A Single-center, Open-label, Fixed-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of SHR3680 With Midazolam (CYP3A4 Substrates), S-Warfarin (CYP2C9 Substrates) and Omeprazole (CYP2C19 Substrates) in Prostate Canc [NCT04676035]Phase 118 participants (Actual)Interventional2020-06-15Completed
Randomized, Placebo-controlled, Parallel-group Study in Healthy Male Subjects to Investigate the Pharmacodynamics During the Switching Procedure From Warfarin to Rivaroxaban [NCT01507051]Phase 196 participants (Actual)Interventional2008-11-30Completed
Comparative Study Evaluating the Effect of the Administration of Vitamin K1 Versus Vitamin K2 on Vascular Calcification in Dialysis Patients [NCT04477811]Phase 2/Phase 340 participants (Actual)Interventional2020-07-25Completed
Vitamin k Status and Its Relation to Vascular Calcification in Hemodialysis Patients in Assiut University Hospital [NCT05060809]Phase 4120 participants (Actual)Interventional2018-01-01Completed
Effects of Vitamin K on Lower-extremity Function in Adults With Osteoarthritis: A Randomized Controlled Pilot Trial [NCT05505552]50 participants (Anticipated)Interventional2023-09-20Recruiting
Late Vitamin K Deficiency-related Bleeding in Neonates (VKDB): Comparison of Four Different Strategies to Prophylaxis Measuring Proteins Induced by Vitamin K Absence (PIVKA) [NCT05713045]80 participants (Actual)Observational2020-03-27Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00150969 (14) [back to overview]Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms.
NCT00150969 (14) [back to overview]Difference in Number of New Cancers by Treatment Arm.
NCT00150969 (14) [back to overview]Difference in Number of New Clinical Fractures by Treatment Arm.
NCT00150969 (14) [back to overview]Difference in Serious Adverse Events
NCT00150969 (14) [back to overview]Effect of Vitamin K1 Supplementation on Level of Bone Resorption Markers (C-telopeptide: CTX)
NCT00150969 (14) [back to overview]Effect of Vitamin K1 Supplementation on Levels of Bone Formation Marker
NCT00150969 (14) [back to overview]Effect of Vitamin K1 Supplementation on Percent of Carboxylation of Osteocalcin
NCT00150969 (14) [back to overview]Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms.
NCT00150969 (14) [back to overview]Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms.
NCT00150969 (14) [back to overview]Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.
NCT00150969 (14) [back to overview]Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.
NCT00150969 (14) [back to overview]Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.
NCT00150969 (14) [back to overview]Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.
NCT00150969 (14) [back to overview]Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms.
NCT00336232 (1) [back to overview]Plasma Phylloquinone
NCT01507051 (42) [back to overview]Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours [AUC(0-24)] of Rivaroxaban After First Dose
NCT01507051 (42) [back to overview]Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours Divided by Dose Per kg Body Weight [AUC(0-24)Norm] of Rivaroxaban After First Dose
NCT01507051 (42) [back to overview]AUC(0-tn) (Area Under the Inverse Measurement Versus Time Curve From Time 0 to the Last Data Point) of Factor Xa Activity
NCT01507051 (42) [back to overview]AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) for PT (Measured as INR=International Normalized Ratio)
NCT01507051 (42) [back to overview]AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Anti-Factor Xa Activity
NCT01507051 (42) [back to overview]AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of aPTT (Activated Partial Thromboplastin Time)
NCT01507051 (42) [back to overview]AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of ETP (Endogenous Thrombin Potential) AUC
NCT01507051 (42) [back to overview]AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of ETP (Endogenous Thrombin Potential) Lag Time
NCT01507051 (42) [back to overview]AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of ETP (Endogenous Thrombin Potential) Peak
NCT01507051 (42) [back to overview]AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of ETP (Endogenous Thrombin Potential) Peak Time
NCT01507051 (42) [back to overview]AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Factor IIa Activity
NCT01507051 (42) [back to overview]AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Factor VIIa Activity
NCT01507051 (42) [back to overview]AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of HepTest (Coagulation Test)
NCT01507051 (42) [back to overview]AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of PiCT (Prothrombinase-induced Clotting Time)
NCT01507051 (42) [back to overview]AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Prothrombin Time (Coagulation Test)
NCT01507051 (42) [back to overview]AUCBA(0-tn) (Baseline Adjusted Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Prothrombin Time (Coagulation Test)
NCT01507051 (42) [back to overview]Emax (Maximum Effect) on Anti-Factor Xa Activity
NCT01507051 (42) [back to overview]Emax (Maximum Effect) on aPTT (Activated Partial Thromboplastin Time)
NCT01507051 (42) [back to overview]Emax (Maximum Effect) on ETP (Endogenous Thrombin Potential) AUC
NCT01507051 (42) [back to overview]Emax (Maximum Effect) on ETP (Endogenous Thrombin Potential) Lag Time
NCT01507051 (42) [back to overview]Emax (Maximum Effect) on ETP (Endogenous Thrombin Potential) Peak
NCT01507051 (42) [back to overview]Emax (Maximum Effect) on ETP (Endogenous Thrombin Potential) Peak Time
NCT01507051 (42) [back to overview]Emax (Maximum Effect) on Factor IIa Activity
NCT01507051 (42) [back to overview]Emax (Maximum Effect) on Factor VIIa Activity
NCT01507051 (42) [back to overview]Emax (Maximum Effect) on HepTest (Coagulation Test)
NCT01507051 (42) [back to overview]Emax (Maximum Effect) on PiCT (Prothrombinase-induced Clotting Time)
NCT01507051 (42) [back to overview]Emax (Maximum Effect) on Prothrombin Time (PT) (Coagulation Test)
NCT01507051 (42) [back to overview]Emax on Factor Xa Activity
NCT01507051 (42) [back to overview]Emax on PT (Measured as INR=International Normalized Ratio)
NCT01507051 (42) [back to overview]Emax,BA (Baseline Adjusted Maximum Effect) on Prothrombin Time (Coagulation Test)
NCT01507051 (42) [back to overview]Half Life Associated With Terminal Slope (t1/2) of R-warfarin After the Last Dose of Warfarin
NCT01507051 (42) [back to overview]Half Life Associated With Terminal Slope (t1/2) of Rivaroxaban After Last Dose
NCT01507051 (42) [back to overview]Half Life Associated With Terminal Slope (t1/2) of S-warfarin After the Last Dose of Warfarin
NCT01507051 (42) [back to overview]Maximum Drug Concentration in Plasma (Cmax) of Rivaroxaban After First Dose
NCT01507051 (42) [back to overview]Maximum Drug Concentration in Plasma Divided by Dose Per kg Body Weight (Cmax,Norm) of Rivaroxaban After First Dose
NCT01507051 (42) [back to overview]Time to Reach Maximum Drug Concentration in Plasma (Tmax) of Rivaroxaban After First Dose
NCT01507051 (42) [back to overview]Drug Concentration in Plasma at Expected Time of Maximum (Peak) Concentration (Cpeak) of Rivaroxaban After Second to Fourth Dose
NCT01507051 (42) [back to overview]Drug Concentration in Plasma at Expected Time of Minimum (Trough) Concentration (Ctrough) of Rivaroxaban After Second to Fourth Dose
NCT01507051 (42) [back to overview]Drug Concentration in Plasma at Steady State at Expected Time of Minimum (Trough) Concentration (Ctrough,ss) of R-warfarin After the Last Dose of Warfarin
NCT01507051 (42) [back to overview]Drug Concentration in Plasma at Steady State at Expected Time of Minimum (Trough) Concentration (Ctrough,ss) of S-warfarin After the Last Dose of Warfarin
NCT01507051 (42) [back to overview]Drug Concentration in Plasma at Steady State at Expected Time of Minimum (Trough) Concentration, Normalized by Dose (Ctrough,ss/D) of R-warfarin After the Last Dose of Warfarin
NCT01507051 (42) [back to overview]Drug Concentration in Plasma at Steady State at Expected Time of Minimum (Trough) Concentration, Normalized by Dose (Ctrough,ss/D) of S-warfarin After the Last Dose of Warfarin

Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms.

BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer (NCT00150969)
Timeframe: 0 to 24 months

Interventionpercentage change in BMD (Mean)
Phyloquinone-1.47
Placebo-1.83

[back to top]

Difference in Number of New Cancers by Treatment Arm.

(NCT00150969)
Timeframe: up to 48 months

Interventionevents (Number)
Phyloquinone3
Placebo12

[back to top]

Difference in Number of New Clinical Fractures by Treatment Arm.

these included fragility fractures (NCT00150969)
Timeframe: up to 48 months

Interventionevents (Number)
Phyloquinone11
Placebo21

[back to top]

Difference in Serious Adverse Events

These include hospitalizations for pneumonia, heart failure, gastro-intestinal bleeding, elective and non-elective surgery, cancer and death. (NCT00150969)
Timeframe: up to 48 months

Interventionevents (Number)
Phyloquinone15
Placebo25

[back to top]

Effect of Vitamin K1 Supplementation on Level of Bone Resorption Markers (C-telopeptide: CTX)

measured by CTX Elisa assay on elecsys platform (NCT00150969)
Timeframe: 0-24 months

Interventionng/ml (Mean)
Phyloquinone0.58
Placebo0.54

[back to top]

Effect of Vitamin K1 Supplementation on Levels of Bone Formation Marker

measured by osteocalcin on elecsys platform (NCT00150969)
Timeframe: 0-24 months

Interventionng/ml (Mean)
Phyloquinone21
Placebo24

[back to top]

Effect of Vitamin K1 Supplementation on Percent of Carboxylation of Osteocalcin

measured by osteocalcin hydroxyapatite binding assay (NCT00150969)
Timeframe: 0 to 24 months

Interventionpercentage of undercarboxylated OC (Mean)
Phyloquinone-21.4
Placebo-2.0

[back to top]

Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms.

BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer (NCT00150969)
Timeframe: 0 to 48 months

Interventionpercentage change in BMD (Mean)
Phyloquinone-5.35
Placebo-5.23

[back to top]

Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms.

BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer (NCT00150969)
Timeframe: 0 to 48 months

Interventionpercentage change in BMD (Mean)
Phyloquinone-2.05
Placebo-2.71

[back to top]

Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.

BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer (NCT00150969)
Timeframe: 0 to 24 months

Interventionpercentage change in BMD (Mean)
Phyloquinone-1.28
Placebo-1.22

[back to top]

Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.

BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer (NCT00150969)
Timeframe: 0 to 48 months

Interventionpercentage change in BMD (Mean)
Phyloquinone-0.40
Placebo-1.76

[back to top]

Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.

BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer (NCT00150969)
Timeframe: 0 to 24 months

Interventionpercentage change in BMD (Mean)
Phyloquinone-0.69
Placebo-0.88

[back to top]

Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.

BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer (NCT00150969)
Timeframe: 0 to 48 months

Interventionpercentage change in BMD (Mean)
Phyloquinone-1.39
Placebo-1.52

[back to top]

Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms.

BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer (NCT00150969)
Timeframe: 0 to 24 months

Interventionpercentage change in BMD (Mean)
Phyloquinone-2.49
Placebo-2.55

[back to top]

Plasma Phylloquinone

Plasma phylloquinone in response to phylloquinone depletion and repletion (NCT00336232)
Timeframe: 2 months

Interventionnmol/L (Mean)
low vitamin Khigh vitamin K
Diet Intervention0.32.3

[back to top]

Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours [AUC(0-24)] of Rivaroxaban After First Dose

The AUC is a measure of systemic drug exposure which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample ([AUC(0-24)] is defined as area under the concentration vs. time curve from zero to 24 hours after first (single) dose). (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban

Interventionmicrog*h/L (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)1639
Rivaroxaban (Xarelto, BAY59-7939)1722

[back to top]

Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours Divided by Dose Per kg Body Weight [AUC(0-24)Norm] of Rivaroxaban After First Dose

The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; [AUC(0-24)norm] is defined as AUC divided by dose per kg body weight from zero to 24 hours after first (single) dose. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban

InterventionKg*h/L (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)6.569
Rivaroxaban (Xarelto, BAY59-7939)6.901

[back to top]

AUC(0-tn) (Area Under the Inverse Measurement Versus Time Curve From Time 0 to the Last Data Point) of Factor Xa Activity

Test to measure the activity of endogenous Factor Xa. AUC(0-tn) of Factor Xa activity was the area under the inverse measurement [100*(Factor Xa activity at baseline (measured as activity per mL) - Factor Xa activity (measured as activity per mL) at different time-points) / Factor Xa activity at baseline (measured as activity per mL)] versus time curve from time 0 to the last data point. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

InterventionPercentage of inhibition*h (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)1238
Warfarin Followed by Placebo834.8
Rivaroxaban (Xarelto, BAY59-7939)514.1

[back to top]

AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) for PT (Measured as INR=International Normalized Ratio)

Prothrombin time - INR measured in seconds that is calculated as INR which is a correction for PT assay differences and an optimization to measure vitamin K antagonists. Higher values than the baseline indicate anticoagulant effects. AUC(0-tn) of PT (INR) was the area under the measurement (PT measured as INR at different time-points divided by PT measured as INR at baseline) versus time curve from time 0 to the last data point. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio*h (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)72.30
Warfarin Followed by Placebo43.60
Rivaroxaban (Xarelto, BAY59-7939)23.21

[back to top]

AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Anti-Factor Xa Activity

This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method. Higher Values than the baseline indicate a more pronounced inhibition. AUC(0-tn) of anti-Factor Xa activity was the area under the measurement (anti-Factor Xa activity [measured in U/L] at different time-points divided by anti-Factor Xa activity [measured in U/L] at baseline) versus time curve from time 0 to the last data point. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio*h (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)124.9
Warfarin Followed by Placebo19.63
Rivaroxaban (Xarelto, BAY59-7939)151.6

[back to top]

AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of aPTT (Activated Partial Thromboplastin Time)

The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V, VIII, IX, X, XI and XII. Higher values than the baseline indicate anticoagulant effects. AUC(0-tn) of aPTT was the area under the measurement (aPTT [measured in seconds] at different time-points divided by aPTT [measured in seconds] at baseline) versus time curve from time 0 to the last data point. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio*h (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)32.48
Warfarin Followed by Placebo22.55
Rivaroxaban (Xarelto, BAY59-7939)21.82

[back to top]

AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of ETP (Endogenous Thrombin Potential) AUC

ETP AUC assesses the overall function of the clotting cascade. The AUC assesses the overall ability to generate thrombin. Decreasing values compared to baseline indicate an anticoagulant effect. AUC(0-tn) of ETP AUC was the area under the measurement (ETP AUC [measured in nm*min as integral of fluorescence measurements] at baseline divided by ETP AUC [measured in nm*min as integral of fluorescence measurements] at different time-points) versus time curve from time 0 to the last data point. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio*h (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)69.69
Warfarin Followed by Placebo51.28
Rivaroxaban (Xarelto, BAY59-7939)18.06

[back to top]

AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of ETP (Endogenous Thrombin Potential) Lag Time

ETP lag time assesses the overall function of the clotting cascade. The lag time assesses the time required until thrombin is generated. Increasing values compared to baseline indicate an anticoagulant effect. AUC(0-tn) of ETP lag time was the area under the measurement (ETP lag time [in minutes as measure for the start of coagulation] at different time-points divided by ETP lag time [in minutes as measure for the start of coagulation] at baseline) versus time curve from time 0 to the last data point. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio*h (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)63.75
Warfarin Followed by Placebo34.93
Rivaroxaban (Xarelto, BAY59-7939)42.79

[back to top]

AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of ETP (Endogenous Thrombin Potential) Peak

ETP peak assesses the overall function of the clotting cascade. The peak assesses the overall maximal ability to generate thrombin. Decreasing values compared to baseline indicate an anticoagulant effect. AUC(0-tn) of ETP peak was the area under the measurement (ETP peak [measured in nm as maximum coagulation activity] at baseline divided by ETP peak measured [in nm as maximum coagulation activity] at different time-points) versus time curve from time 0 to the last data point. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio*h (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)166.8
Warfarin Followed by Placebo46.75
Rivaroxaban (Xarelto, BAY59-7939)74.67

[back to top]

AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of ETP (Endogenous Thrombin Potential) Peak Time

ETP peak time assesses the overall function of the clotting cascade. The peak time assesses the time required to reach the maximal thrombin generation. Increasing values compared to baseline indicate an anticoagulant effect. AUC(0-tn) of ETP peak time was the area under the measurement (ETP peak time [measured in minutes as time to reach the maximum coagulation activity] at different time-points divided by ETP peak time [measured in minutes as time to reach the maximum coagulation activity] at baseline) versus time curve from time 0 to the last data point. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio*h (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)49.14
Warfarin Followed by Placebo19.83
Rivaroxaban (Xarelto, BAY59-7939)55.58

[back to top]

AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Factor IIa Activity

Factor II (Thrombin) is a coagulation factor that is required for the coagulation process. AUC(0-tn) of Factor IIa activity was the area under the measurement (Factor IIa activity [measured as percent of actual Factor IIa activity compared to Factor IIa activity in reference plasma] at baseline divided by Factor IIa activity [measured as percent of actual Factor IIa activity compared to Factor IIa activity in reference plasma] at different time-points) versus time curve from time 0 to the last data point. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio*h (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)62.26
Warfarin Followed by Placebo58.60
Rivaroxaban (Xarelto, BAY59-7939)3.908

[back to top]

AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Factor VIIa Activity

Factor VII is a coagulation factor that is required for the coagulation process. AUC(0-tn) of Factor VIIa activity was the area under the measurement (Factor VIIa activity [measured as percent of actual Factor VIIa activity compared to Factor VIIa activity in reference plasma] at baseline divided by Factor VIIa activity [measured as percent of actual Factor VIIa activity compared to Factor VIIa activity in reference plasma] at different time-points) versus time curve from time 0 to the last data point. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio*h (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)134.2
Warfarin Followed by Placebo94.83
Rivaroxaban (Xarelto, BAY59-7939)9.283

[back to top]

AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of HepTest (Coagulation Test)

This coagulation test was developed to monitor heparin and especially low-molecular weight heparins (LMWH). It is sensitive to measure Factor X. Higher values than the baseline indicate anticoagulant effects. AUC(0-tn) of HepTest was the area under the measurement (HepTest [measured in seconds] at different time-points divided by HepTest [measured in seconds] at baseline) versus time curve from time 0 to the last data point. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio*h (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)27.37
Warfarin Followed by Placebo15.08
Rivaroxaban (Xarelto, BAY59-7939)28.25

[back to top]

AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of PiCT (Prothrombinase-induced Clotting Time)

This coagulation test can be adapted to measure different anticoagulants, including inhibitors of Factor X. Higher values than the baseline indicate anticoagulant effects. AUC(0-tn) of PiCT was the area under the measurement (PiCT [measured in seconds] at different time-points divided by PiCT [measured in seconds] at baseline) versus time curve from time 0 to the last data point. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio*h (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)37.36
Warfarin Followed by Placebo4.221
Rivaroxaban (Xarelto, BAY59-7939)39.20

[back to top]

AUC(0-tn) (Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Prothrombin Time (Coagulation Test)

Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. Higher values than the baseline indicate anticoagulant effects. AUC(0-tn) of PT was the area under the measurement (PT [measured in seconds] at different time-points divided by PT [measured in seconds] at baseline) versus time curve from time 0 to the last data point. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio*h (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)55.36
Warfarin Followed by Placebo37.89
Rivaroxaban (Xarelto, BAY59-7939)20.41

[back to top]

AUCBA(0-tn) (Baseline Adjusted Area Under the Measurement Versus Time Curve From Time 0 to the Last Data Point) of Prothrombin Time (Coagulation Test)

Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. Higher values than the baseline indicate anticoagulant effects. AUCBA(0-tn) of PT was the area under the measurement (PT [measured in seconds] at different time-points minus PT [measured in seconds] at baseline) versus time curve from time 0 to the last data point. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventions*h (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)413.4
Warfarin Followed by Placebo179.9
Rivaroxaban (Xarelto, BAY59-7939)33.06

[back to top]

Emax (Maximum Effect) on Anti-Factor Xa Activity

This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method. Higher Values than the baseline indicate a more pronounced inhibition. Emax on anti-Factor Xa activity was measured as the ratio of maximum anti-Factor Xa activity (measured in U/L) divided by anti-Factor Xa activity (measured in U/L) at baseline. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)15.83
Warfarin Followed by Placebo2.281
Rivaroxaban (Xarelto, BAY59-7939)18.57

[back to top]

Emax (Maximum Effect) on aPTT (Activated Partial Thromboplastin Time)

The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V, VIII, IX, X, XI and XII. Higher values than the baseline indicate anticoagulant effects. Emax on aPTT was measured as the ratio of maximum aPTT (measured in seconds) divided by aPTT (measured in seconds) at baseline. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)1.843
Warfarin Followed by Placebo1.304
Rivaroxaban (Xarelto, BAY59-7939)1.409

[back to top]

Emax (Maximum Effect) on ETP (Endogenous Thrombin Potential) AUC

ETP AUC assesses the overall function of the clotting cascade. The AUC assesses the overall ability to generate thrombin. Decreasing values compared to baseline indicate an anticoagulant effect. Emax on ETP AUC was measured as the ratio of ETP AUC (measured in nm*min as integral of fluorescence measurements) at baseline divided by minimum ETP AUC (measured in nm*min as integral of fluorescence measurements). (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)4.257
Warfarin Followed by Placebo2.610
Rivaroxaban (Xarelto, BAY59-7939)1.813

[back to top]

Emax (Maximum Effect) on ETP (Endogenous Thrombin Potential) Lag Time

ETP lag time assesses the overall function of the clotting cascade. The lag time assesses the time required until thrombin is generated. Increasing values compared to baseline indicate an anticoagulant effect. Emax on ETP lag time was measured as the ratio of maximum ETP lag time (in minutes as measure for the start of coagulation) divided by ETP lag time (in minutes as measure for the start of coagulation) at baseline. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)3.954
Warfarin Followed by Placebo1.748
Rivaroxaban (Xarelto, BAY59-7939)2.569

[back to top]

Emax (Maximum Effect) on ETP (Endogenous Thrombin Potential) Peak

ETP peak assesses the overall function of the clotting cascade. The peak assesses the overall maximal ability to generate thrombin. Decreasing values compared to baseline indicate an anticoagulant effect. Emax on ETP peak was measured as the ratio of ETP peak (measured in nm as maximum coagulation activity) at baseline divided by minimum ETP peak (measured in nm as maximum coagulation activity). (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)18.73
Warfarin Followed by Placebo2.523
Rivaroxaban (Xarelto, BAY59-7939)6.758

[back to top]

Emax (Maximum Effect) on ETP (Endogenous Thrombin Potential) Peak Time

ETP peak time assesses the overall function of the clotting cascade. The peak time assesses the time required to reach the maximal thrombin generation. Increasing values compared to baseline indicate an anticoagulant effect. Emax on ETP peak time was measured as the ratio of maximum ETP peak time (measured in minutes as time to reach the maximum coagulation activity) divided by ETP peak time (measured in minutes as time to reach the maximum coagulation activity) at baseline. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)4.164
Warfarin Followed by Placebo1.375
Rivaroxaban (Xarelto, BAY59-7939)3.790

[back to top]

Emax (Maximum Effect) on Factor IIa Activity

Factor II (Thrombin) is a coagulation factor that is required for the coagulation process. Emax on Factor IIa activity was measured as the ratio of Factor IIa activity (measured as percent of actual Factor IIa activity compared to Factor IIa activity in reference plasma) at baseline divided by minimum Factor IIa activity (measured as percent of actual Factor IIa activity compared to Factor IIa activity in reference plasma). (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)3.166
Warfarin Followed by Placebo2.958
Rivaroxaban (Xarelto, BAY59-7939)1.126

[back to top]

Emax (Maximum Effect) on Factor VIIa Activity

Factor VII is a coagulation factor that is required for the coagulation process. Emax on Factor VIIa activity was measured as the ratio of Factor VIIa activity (measured as percent of actual Factor VIIa activity compared to Factor VIIa activity in reference plasma) at baseline divided by minimum Factor VIIa activity (measured as percent of actual Factor VIIa activity compared to Factor VIIa activity in reference plasma). (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)12.80
Warfarin Followed by Placebo6.769
Rivaroxaban (Xarelto, BAY59-7939)1.346

[back to top]

Emax (Maximum Effect) on HepTest (Coagulation Test)

This coagulation test was developed to monitor heparin and especially low-molecular weight heparins (LMWH). It is sensitive to measure Factor X. Higher values than the baseline indicate anticoagulant effects. Emax on HepTest was measured as the ratio of maximum HepTest (measured in seconds) divided by HepTest (measured in seconds) at baseline. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)2.148
Warfarin Followed by Placebo1.163
Rivaroxaban (Xarelto, BAY59-7939)2.009

[back to top]

Emax (Maximum Effect) on PiCT (Prothrombinase-induced Clotting Time)

This coagulation test can be adapted to measure different anticoagulants, including inhibitors of Factor X. Higher values than the baseline indicate anticoagulant effects. Emax on PiCT was measured as the ratio of maximum PiCT (measured in seconds) divided by PiCT (measured in seconds) at baseline. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)3.158
Warfarin Followed by Placebo1.139
Rivaroxaban (Xarelto, BAY59-7939)2.723

[back to top]

Emax (Maximum Effect) on Prothrombin Time (PT) (Coagulation Test)

Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. Higher values than the baseline indicate anticoagulant effects. Emax on PT was measured as the ratio of maximum PT (measured in seconds) divided by PT (measured in seconds) at baseline. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)4.393
Warfarin Followed by Placebo1.884
Rivaroxaban (Xarelto, BAY59-7939)1.573

[back to top]

Emax on Factor Xa Activity

Test to measure the activity of endogenous Factor Xa. Emax on Factor Xa activity was calculated as 100*(Factor Xa activity at baseline [measured as activity per mL] - minimum of Factor Xa activity [measured as activity per mL]) / Factor Xa activity at baseline [measured as activity per mL]. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

InterventionPercentage of inhibition (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)75.95
Warfarin Followed by Placebo43.41
Rivaroxaban (Xarelto, BAY59-7939)49.73

[back to top]

Emax on PT (Measured as INR=International Normalized Ratio)

Prothrombin time - INR measured in seconds that is calculated as INR which is a correction for PT assay differences and an optimization to measure vitamin K antagonists. Higher values than the baseline indicate anticoagulant effects. Emax on PT (INR) was measured as the ratio of maximum INR divided by baseline INR. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionratio (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)6.655
Warfarin Followed by Placebo2.250
Rivaroxaban (Xarelto, BAY59-7939)1.793

[back to top]

Emax,BA (Baseline Adjusted Maximum Effect) on Prothrombin Time (Coagulation Test)

Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. Higher values than the baseline indicate anticoagulant effects. Emax,BA on PT was measured as maximum PT (measured in seconds) minus PT (measured in seconds) at baseline. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban or placebo

Interventionseconds (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)44.98
Warfarin Followed by Placebo11.59
Rivaroxaban (Xarelto, BAY59-7939)7.31

[back to top]

Half Life Associated With Terminal Slope (t1/2) of R-warfarin After the Last Dose of Warfarin

Half-life refers to the elimination of the drug, i.e. the time it takes for the blood plasma concentration to reach half the concentration in the terminal phase of elimination. (NCT01507051)
Timeframe: Blood samples taken at 24, 30, 48, 54, 72, 96, and 120 h after the last administration of warfarin

Interventionhours (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)40.08
Warfarin Followed by Placebo40.24

[back to top]

Half Life Associated With Terminal Slope (t1/2) of Rivaroxaban After Last Dose

Half-life refers to the elimination of the drug, i.e. the time it takes for the blood plasma concentration to reach half the concentration in the terminal phase of elimination. (NCT01507051)
Timeframe: 3, 24, 48, and 72 h after the last administration of rivaroxaban

Interventionhours (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)6.885
Rivaroxaban (Xarelto, BAY59-7939)6.931

[back to top]

Half Life Associated With Terminal Slope (t1/2) of S-warfarin After the Last Dose of Warfarin

Half-life refers to the elimination of the drug, i.e. the time it takes for the blood plasma concentration to reach half the concentration in the terminal phase of elimination. (NCT01507051)
Timeframe: Blood samples taken at 24, 30, 48, 54, 72, 96, and 120 h after the last administration of warfarin

Interventionhours (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)28.24
Warfarin Followed by Placebo27.08

[back to top]

Maximum Drug Concentration in Plasma (Cmax) of Rivaroxaban After First Dose

Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban

Interventionmicrog/L (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)219.8
Rivaroxaban (Xarelto, BAY59-7939)221.0

[back to top]

Maximum Drug Concentration in Plasma Divided by Dose Per kg Body Weight (Cmax,Norm) of Rivaroxaban After First Dose

Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; Cmax,norm is defined as Cmax divided by dose (mg) per kg body weight. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban

InterventionKg/L (Geometric Mean)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)0.8812
Rivaroxaban (Xarelto, BAY59-7939)0.8857

[back to top]

Time to Reach Maximum Drug Concentration in Plasma (Tmax) of Rivaroxaban After First Dose

Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content. (NCT01507051)
Timeframe: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban

Interventionhours (Median)
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)3.008
Rivaroxaban (Xarelto, BAY59-7939)3.000

[back to top]

Drug Concentration in Plasma at Expected Time of Maximum (Peak) Concentration (Cpeak) of Rivaroxaban After Second to Fourth Dose

Cpeak refers to the time after dosing when the drug concentration is expected to reach its maximum (peak) concentration. (NCT01507051)
Timeframe: Always 3 h after second, third, and fourth dose

,
InterventionMicrog/L (Geometric Mean)
second dosethird dosefourth dose
Rivaroxaban (Xarelto, BAY59-7939)206.7201.0214.5
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)211.2206.1201.4

[back to top]

Drug Concentration in Plasma at Expected Time of Minimum (Trough) Concentration (Ctrough) of Rivaroxaban After Second to Fourth Dose

Ctrough refers to the time after dosing when the drug concentration is expected to reach its minimum (trough) concentration. (NCT01507051)
Timeframe: Always 24 h after the second, third, and fourth dose

,
InterventionMicrog/L (Geometric Mean)
second dosethird dosefourth dose
Rivaroxaban (Xarelto, BAY59-7939)17.0715.8515.61
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)13.0614.3412.43

[back to top]

Drug Concentration in Plasma at Steady State at Expected Time of Minimum (Trough) Concentration (Ctrough,ss) of R-warfarin After the Last Dose of Warfarin

Ctrough,ss refers to the drug concentration at steady state at the time when it is expected to reach its minimum (trough) concentration. (NCT01507051)
Timeframe: 0 h (predose) and 24 h after the last administration of warfarin

,
InterventionMicrog/L (Geometric Mean)
before last administrationafter last administration
Warfarin Followed by Placebo721.8702.8
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)754.4740.2

[back to top]

Drug Concentration in Plasma at Steady State at Expected Time of Minimum (Trough) Concentration (Ctrough,ss) of S-warfarin After the Last Dose of Warfarin

Ctrough,ss refers to the drug concentration at steady state at the time when it is expected to reach its minimum (trough) concentration. (NCT01507051)
Timeframe: 0 h (predose) and 24 h after the last administration of warfarin

,
InterventionMicrog/L (Geometric Mean)
before last administrationafter last administration
Warfarin Followed by Placebo429.9424.9
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)498.2478.4

[back to top]

Drug Concentration in Plasma at Steady State at Expected Time of Minimum (Trough) Concentration, Normalized by Dose (Ctrough,ss/D) of R-warfarin After the Last Dose of Warfarin

Ctrough,ss/D refers to the drug concentration at steady state at the time when it is expected to reach its minimum (trough) concentration, normalized by dose. (NCT01507051)
Timeframe: 0 h (predose) and 24 h after the last administration of warfarin

,
Intervention1/Liter (Geometric Mean)
before last administrationafter last administration
Warfarin Followed by Placebo0.078430.07915
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)0.071540.08633

[back to top]

Drug Concentration in Plasma at Steady State at Expected Time of Minimum (Trough) Concentration, Normalized by Dose (Ctrough,ss/D) of S-warfarin After the Last Dose of Warfarin

Ctrough,ss/D refers to the drug concentration at steady state at the time when it is expected to reach its minimum (trough) concentration, normalized by dose. (NCT01507051)
Timeframe: 0 h (predose) and 24 h after the last administration of warfarin

,
Intervention1/Liter (Geometric Mean)
before last administrationafter last administration
Warfarin Followed by Placebo0.046710.04786
Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)0.047240.05580

[back to top]